Vaccines

FDA Approves GSK’s Shingles Vaccine

October 27, 2017

The vaccine is approved for the prevention of shingles in adult patients aged 50 years and older.

Inovio Reports on DNA Vaccine It is Developing with US Army

October 26, 2017

Inovio has reported results from a study with non-human primates that showed 100% effectiveness with a DNA vaccine the company is developing with the US Army.

Lilly and CureVac Partner on mRNA Cancer Vaccines in $1.8-Billion Deal

October 20, 2017

The companies aim to use CureVac’s proprietary messenger RNA technology to develop and commercialize up to five potential cancer vaccine products.

DCPrime and Apceth Biopharma Collaborate on Cancer Vaccines

October 19, 2017

The two companies announced their collaboration for the production and development of cancer vaccines.

Japanese Agency Supports Daiichi Sankyo’s Genetic Vaccine Platform

October 16, 2017

Through the support of the Japanese agency, Daiichi Sankyo intends to further develop its genetic vaccine platform focused around its new nucleic acid delivery technology.

GSK’s Shingles Vaccine Approved in Canada

October 16, 2017

The vaccine is a non-live, recombinant subunit vaccine that combines an antigen and an adjuvant system to trigger a targeted and long-lasting immune response to the shingle-causing virus.

Sanofi to Expand Influenza Vaccine Production Facility

October 12, 2017

The company is investing EUR 170 million (US$201 million) to expand its vaccine manufacturing site in France for its newest influenza vaccine.

SGS and Bavarian Nordic Form Vaccine Pact

October 12, 2017

PTSM: Pharmaceutical Technology Sourcing and Management

The collaboration will focus on developing a novel and differentiated challenge model for respiratory syncytial virus.

BARDA Funds Ebola Vaccine and Drug Development

October 04, 2017

Under Project BioShield, the agency could provide more than $170 million in funding to purchase and support late-stage development of Ebola vaccines and therapeutic drugs.

Bavarian Nordic Secures BARDA Contract for Smallpox Vaccine

October 04, 2017

The Danish biotechnology company has been awarded a sole-source BARDA contract valued at more than $539 million for a freeze-dried smallpox vaccine.